Manufacturing Batch Quality: FDA Should Consider Parametric Test, GSK Says
Executive Summary
FDA should consider implementing a parametric tolerance interval (PTI) test to evaluate batch quality, GSK suggested at an Oct. 21 Pharmaceutical Science Advisory Committee meeting in Rockville, Md
You may also be interested in...
“Orally Disintegrating” Definition: FDA Considers 60-Second Time Limit
FDA is considering defining an "orally disintegrating" tablet as one that dissolves in 60 seconds or less
“Orally Disintegrating” Definition: FDA Considers 60-Second Time Limit
FDA is considering defining an "orally disintegrating" tablet as one that dissolves in 60 seconds or less
FDA “Quality By Design” Initially Focuses On Post-Approval Manufacturing
FDA will focus initially on the post-approval regulatory pathway as the most likely starting point for firms instituting "quality by design" manufacturing